trimethylamine has been researched along with Inflammation in 11 studies
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Endothelial dysfunction is a critical initiating factor contributing to cardiovascular diseases, involving the gut microbiome-derived metabolite trimethylamine N-oxide (TMAO)." | 8.31 | Time-dependent specific molecular signatures of inflammation and remodelling are associated with trimethylamine-N-oxide (TMAO)-induced endothelial cell dysfunction. ( Bellanger, S; Cheong, KH; Chin, YL; Devasia, AG; Leo, CH; Ong, ES; Ramasamy, A; Shanmugham, M, 2023) |
| "Evidence shows that trimethylamine (TMA)/trimethylamine-N-oxide (TMAO) is closely related to non-alcoholic fatty liver disease (NAFLD)." | 8.12 | Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine. ( Cao, P; Chen, Q; Deng, W; Gong, Z; Guo, J; Li, X; Pei, M; Shi, C; Wang, L; Wang, Y; Zhang, L, 2022) |
| "Trimethylamine-N-oxide (TMAO), a gut-microbiota-dependent metabolite after ingesting dietary choline, has been identified as a novel risk factor for atherosclerosis through inducing vascular inflammation." | 8.12 | Gut-Flora-Dependent Metabolite Trimethylamine-N-Oxide Promotes Atherosclerosis-Associated Inflammation Responses by Indirect ROS Stimulation and Signaling Involving AMPK and SIRT1. ( Hong, Y; Ji, N; Luo, X; Ma, W; Nie, Z; Shan, J; Xue, J; Zhang, T; Zhang, Y; Zhou, S; Zhu, W, 2022) |
| " We aimed to evaluate whether residual risk of recurrent stroke of TMAO and its precursor choline remain among patients who received dual-antiplatelet therapy and intensive lipid-lowering therapy and with a low inflammation level (high-sensitivity C-reactive protein <2 mg/L on admission)." | 8.12 | Residual Risk of Trimethylamine-N-Oxide and Choline for Stroke Recurrence in Patients With Intensive Secondary Therapy. ( Cheng, A; Jiang, X; Jin, A; Li, H; Li, K; Lin, J; Meng, X; Wang, Y; Xu, J; Xue, J; Zhao, M; Zheng, L, 2022) |
| "Atherosclerosis is a chronic inflammatory disease of the arterial wall involving inflammation, redox imbalance, and impaired cholesterol transport." | 5.72 | Chronic oral trimethylamine-N-oxide administration induces experimental incipient atherosclerosis in non-genetically modified mice. ( Ancuta, B; Cismaru, G; Decea, N; Filip, GA; Florea, CM; Moldovan, R; Rosu, R; Toma, V; Vlase, L, 2022) |
| "Endothelial dysfunction is a critical initiating factor contributing to cardiovascular diseases, involving the gut microbiome-derived metabolite trimethylamine N-oxide (TMAO)." | 4.31 | Time-dependent specific molecular signatures of inflammation and remodelling are associated with trimethylamine-N-oxide (TMAO)-induced endothelial cell dysfunction. ( Bellanger, S; Cheong, KH; Chin, YL; Devasia, AG; Leo, CH; Ong, ES; Ramasamy, A; Shanmugham, M, 2023) |
| "Evidence shows that trimethylamine (TMA)/trimethylamine-N-oxide (TMAO) is closely related to non-alcoholic fatty liver disease (NAFLD)." | 4.12 | Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine. ( Cao, P; Chen, Q; Deng, W; Gong, Z; Guo, J; Li, X; Pei, M; Shi, C; Wang, L; Wang, Y; Zhang, L, 2022) |
| "Trimethylamine-N-oxide (TMAO), a gut-microbiota-dependent metabolite after ingesting dietary choline, has been identified as a novel risk factor for atherosclerosis through inducing vascular inflammation." | 4.12 | Gut-Flora-Dependent Metabolite Trimethylamine-N-Oxide Promotes Atherosclerosis-Associated Inflammation Responses by Indirect ROS Stimulation and Signaling Involving AMPK and SIRT1. ( Hong, Y; Ji, N; Luo, X; Ma, W; Nie, Z; Shan, J; Xue, J; Zhang, T; Zhang, Y; Zhou, S; Zhu, W, 2022) |
| " We aimed to evaluate whether residual risk of recurrent stroke of TMAO and its precursor choline remain among patients who received dual-antiplatelet therapy and intensive lipid-lowering therapy and with a low inflammation level (high-sensitivity C-reactive protein <2 mg/L on admission)." | 4.12 | Residual Risk of Trimethylamine-N-Oxide and Choline for Stroke Recurrence in Patients With Intensive Secondary Therapy. ( Cheng, A; Jiang, X; Jin, A; Li, H; Li, K; Lin, J; Meng, X; Wang, Y; Xu, J; Xue, J; Zhao, M; Zheng, L, 2022) |
| "Atherosclerosis is a hallmark of cardiovascular disease, and lifestyle strongly impacts its onset and progression." | 1.72 | TMAO Upregulates Members of the miR-17/92 Cluster and Impacts Targets Associated with Atherosclerosis. ( Blanco, R; Daimiel, L; Dávalos, A; Díez-Ricote, L; Micó, V; Ordovás, JM; Ruiz-Valderrey, P; Tomé-Carneiro, J, 2022) |
| "Atherosclerosis is a chronic inflammatory disease of the arterial wall involving inflammation, redox imbalance, and impaired cholesterol transport." | 1.72 | Chronic oral trimethylamine-N-oxide administration induces experimental incipient atherosclerosis in non-genetically modified mice. ( Ancuta, B; Cismaru, G; Decea, N; Filip, GA; Florea, CM; Moldovan, R; Rosu, R; Toma, V; Vlase, L, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 10 (90.91) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, C | 1 |
| Pei, M | 1 |
| Wang, Y | 3 |
| Chen, Q | 1 |
| Cao, P | 1 |
| Zhang, L | 1 |
| Guo, J | 1 |
| Deng, W | 1 |
| Wang, L | 1 |
| Li, X | 1 |
| Gong, Z | 1 |
| Zhou, S | 1 |
| Xue, J | 2 |
| Shan, J | 1 |
| Hong, Y | 1 |
| Zhu, W | 1 |
| Nie, Z | 1 |
| Zhang, Y | 1 |
| Ji, N | 1 |
| Luo, X | 1 |
| Zhang, T | 2 |
| Ma, W | 1 |
| Xu, J | 1 |
| Zhao, M | 1 |
| Jin, A | 1 |
| Cheng, A | 1 |
| Jiang, X | 1 |
| Li, K | 1 |
| Lin, J | 1 |
| Meng, X | 1 |
| Li, H | 1 |
| Zheng, L | 1 |
| Díez-Ricote, L | 1 |
| Ruiz-Valderrey, P | 1 |
| Micó, V | 1 |
| Blanco, R | 1 |
| Tomé-Carneiro, J | 1 |
| Dávalos, A | 1 |
| Ordovás, JM | 1 |
| Daimiel, L | 1 |
| Florea, CM | 2 |
| Rosu, R | 2 |
| Cismaru, G | 1 |
| Moldovan, R | 2 |
| Vlase, L | 1 |
| Toma, V | 1 |
| Decea, N | 2 |
| Ancuta, B | 1 |
| Filip, GA | 2 |
| Samaan, E | 1 |
| Eldeeb, AA | 1 |
| Ibrahim, AB | 1 |
| Erman, M | 1 |
| Sabry, AA | 1 |
| Mahmoud, MA | 1 |
| Baldea, I | 1 |
| Shanmugham, M | 1 |
| Devasia, AG | 1 |
| Chin, YL | 1 |
| Cheong, KH | 1 |
| Ong, ES | 1 |
| Bellanger, S | 1 |
| Ramasamy, A | 1 |
| Leo, CH | 1 |
| Liu, J | 1 |
| Si, C | 1 |
| Wang, X | 1 |
| Wang, RT | 1 |
| Lv, Z | 1 |
| Macpherson, ME | 1 |
| Hov, JR | 1 |
| Ueland, T | 1 |
| Dahl, TB | 1 |
| Kummen, M | 1 |
| Otterdal, K | 1 |
| Holm, K | 1 |
| Berge, RK | 1 |
| Mollnes, TE | 1 |
| Trøseid, M | 1 |
| Halvorsen, B | 1 |
| Aukrust, P | 1 |
| Fevang, B | 1 |
| Jørgensen, SF | 1 |
| Rohrmann, S | 1 |
| Linseisen, J | 1 |
| Allenspach, M | 1 |
| von Eckardstein, A | 1 |
| Müller, D | 1 |
11 other studies available for trimethylamine and Inflammation
| Article | Year |
|---|---|
Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine.
Topics: Animals; Cell Line; Endoplasmic Reticulum Chaperone BiP; Gastrointestinal Microbiome; Gene Silencing | 2022 |
Gut-Flora-Dependent Metabolite Trimethylamine-N-Oxide Promotes Atherosclerosis-Associated Inflammation Responses by Indirect ROS Stimulation and Signaling Involving AMPK and SIRT1.
Topics: AMP-Activated Protein Kinases; Animals; Atherosclerosis; Choline; Gastrointestinal Microbiome; Infla | 2022 |
Residual Risk of Trimethylamine-N-Oxide and Choline for Stroke Recurrence in Patients With Intensive Secondary Therapy.
Topics: C-Reactive Protein; Choline; Humans; Inflammation; Lipids; Methylamines; Oxides; Platelet Aggregatio | 2022 |
TMAO Upregulates Members of the miR-17/92 Cluster and Impacts Targets Associated with Atherosclerosis.
Topics: Animals; Atherosclerosis; Betaine; Cardiovascular Diseases; Carnitine; Choline; Humans; Inflammation | 2022 |
Chronic oral trimethylamine-N-oxide administration induces experimental incipient atherosclerosis in non-genetically modified mice.
Topics: Animals; Atherosclerosis; C-Reactive Protein; Cholesterol; Inflammation; Male; Mice; Oxides; Rats; R | 2022 |
Effect of Ramadan fasting on chronic inflammation markers and gut bacterial endotoxins among Egyptian hemodialysis patients.
Topics: C-Reactive Protein; Egypt; Fasting; Gastrointestinal Microbiome; Humans; Inflammation; Prospective S | 2023 |
The Acute Effect of Trimethylamine-N-Oxide on Vascular Function, Oxidative Stress, and Inflammation in Rat Aortic Rings.
Topics: Animals; Inflammation; NF-E2-Related Factor 2; NF-kappa B; Oxidative Stress; Oxides; Rats; Superoxid | 2023 |
Time-dependent specific molecular signatures of inflammation and remodelling are associated with trimethylamine-N-oxide (TMAO)-induced endothelial cell dysfunction.
Topics: Endothelial Cells; Humans; Inflammation; Methylamines; Oxides; Vascular Diseases | 2023 |
Baicalin ameliorates neuropathology in repeated cerebral ischemia-reperfusion injury model mice by remodeling the gut microbiota.
Topics: Animals; Brain; Clusterin; Cytokines; Disease Models, Animal; Flavonoids; Gastrointestinal Microbiom | 2020 |
Gut Microbiota-Dependent Trimethylamine N-Oxide Associates With Inflammation in Common Variable Immunodeficiency.
Topics: Adult; Bacteria; Bacterial Proteins; Biomarkers; Carnitine; Common Variable Immunodeficiency; Diet; | 2020 |
Plasma Concentrations of Trimethylamine-N-oxide Are Directly Associated with Dairy Food Consumption and Low-Grade Inflammation in a German Adult Population.
Topics: Adult; Animals; Betaine; C-Reactive Protein; Choline; Dairy Products; Diet; Diet Surveys; Feeding Be | 2016 |